January 2026 Research Update

This month, one real-world study added a clearer message about vision in Bardet-Biedl syndrome (BBS): the specific gene change a person has may relate to how severe their eyesight problems are. In a Puerto Rico group of people with genetically confirmed BBS, BBS1 variants were very common, and people with two copies of a BBS1 variant (homozygous) tended to have worse visual acuity than those with two different BBS1 variants (compound heterozygous). This kind of result does not predict what will happen to any one person, but it helps explain why vision can vary across families and across people with BBS. [1]

The same study also measured retinal structure with eye imaging and found retinal thinning and signs of photoreceptor layer disruption in this group, which fits with the known pattern of retinal degeneration in BBS. Differences in macular thickness and volume were not clearly separated between gene groups in these data, even though visual acuity differed for one eye comparison. Taken together, the report points to genotype (the specific BBS1 setup) as one possible piece of the vision story, while also showing that not every eye measure lines up neatly with gene category in a small retrospective dataset. [1]

For patients and caregivers, this month mainly adds understanding about why vision outcomes can differ in BBS, even among people with the same named gene (BBS1). The evidence comes from a single retrospective clinic-based group, so it is more about spotting patterns than giving firm predictions for an individual. What remains uncertain is how well these differences hold up in larger groups and over time, since this report did not follow people forward to track progression. [1]

This month, laboratory research added an early clue about how BBS genes might affect hormone-related organs as they develop. In mice missing the BBS4 gene, the pituitary gland (a hormone control gland in the brain) was smaller in adulthood and showed a shift in the mix of hormone-producing cells, with more gonadotrophs. These findings suggest that normal cilia function (the cell structures affected in BBS) may be important for pituitary growth after birth. [2]

The same mouse work linked the smaller pituitary to changes in a growth-and-patterning signal called Hedgehog signaling, which was mildly reduced during development and less responsive in isolated pituitary stem cells. The study also reported lower levels of some stem cell markers in those cells, which is one possible explanation for reduced growth. This is not patient outcome data, but it helps build a biological picture that could connect BBS gene function to hormonal and growth-related features seen in the syndrome. [2]

For families, this is mainly early-stage research that may matter later if confirmed in people. It supports the idea that some BBS features related to growth, puberty, or reproductive development could be tied to how cilia-related genes shape hormone glands during development, but the study did not test symptoms or treatments in patients. What remains uncertain is how closely the mouse pituitary changes match the range of hormone findings in human BBS, and whether this line of research will lead to specific tests or therapies in the future. [2]

This month included a single case report that highlights how BBS can sometimes be recognized very early, even in infancy, when obesity and other typical physical features appear together. The infant in the report had early-onset obesity along with features such as polydactyly and micropenis, and genetic testing confirmed a BBS4 mutation. The report mainly reinforces that genetic testing can sometimes provide a clear diagnosis when multiple BBS features are present early in life. [3]

The case also noted a plan to start setmelanotide (a medicine used for certain genetic forms of obesity) for weight management at follow-up, but it did not report treatment results. Because it is one patient, it cannot tell how common this presentation is or what outcomes to expect. Its value is in showing one example of the diagnostic path and the types of care discussions that may happen after genetic confirmation. [3]

For patients and caregivers, this is a reminder that BBS can sometimes be confirmed through genetic testing early in life when the signs fit, which may help families understand the cause of a child's symptoms. This report does not show whether setmelanotide helped this child, so it does not add new evidence about benefits or risks of that medicine. What remains uncertain is how often infants with early-onset obesity have BBS versus other causes, since a single case cannot answer that question. [3]